Terms: = Breast cancer AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Clinical Outcome
925 results:
1. Molecular features of luminal breast cancer defined through spatial and single-cell transcriptomics.
Yoshitake R; Mori H; Ha D; Wu X; Wang J; Wang X; Saeki K; Chang G; Shim HJ; Chan Y; Chen S
Clin Transl Med; 2024 Jan; 14(1):e1548. PubMed ID: 38282415
[TBL] [Abstract] [Full Text] [Related]
2. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
3. Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients.
Saldajeno DP; Kawaoka S; Masuda N; Tanaka S; Bando H; Nishimura T; Kadoya T; Yamanaka T; Imoto S; Velaga RM; Tamura N; Aruga T; Ikeda K; Fukui Y; Maeshima Y; Takada M; Suzuki E; Ueno T; Ogawa S; Haga H; Ohno S; Morita S; Kawaguchi K; Toi M
Br J Cancer; 2024 Apr; 130(6):1023-1035. PubMed ID: 38238427
[TBL] [Abstract] [Full Text] [Related]
4. LncRNA SOX9-AS1 triggers a transcriptional program involved in lipid metabolic reprogramming, cell migration and invasion in triple-negative breast cancer.
Cisneros-Villanueva M; Fonseca-Montaño MA; Ríos-Romero M; López-Camarillo C; Jiménez-Morales S; Langley E; Rosette-Rueda AS; Cedro-Tanda A; Hernández-Sotelo D; Hidalgo-Miranda A
Sci Rep; 2024 Jan; 14(1):1483. PubMed ID: 38233470
[TBL] [Abstract] [Full Text] [Related]
5. Effectiveness and toxicity of five-fraction prone accelerated partial breast irradiation.
Hardy-Abeloos C; Xiao J; Oh C; Barbee D; Shah B; Maisonet O; Perez C; Adams S; Schnabel F; Axelrod D; Guth A; Karp N; Cahlon O; Gerber N
Breast Cancer Res Treat; 2024 Apr; 204(3):485-495. PubMed ID: 38183516
[TBL] [Abstract] [Full Text] [Related]
6. Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes.
Dimitrakopoulos FI; Goussia A; Koliou GA; Dadouli K; Batistatou A; Kourea HP; Bobos M; Arapantoni-Dadioti P; Tzaida O; Koletsa T; Chrisafi S; Sotiropoulou M; Papoudou-Bai A; Nicolaou I; Charchanti A; Mauri D; Aravantinos G; Binas I; Res E; Psyrri A; Pectasides D; Bafaloukos D; Koumarianou A; Bompolaki I; Rigakos G; Karanikiotis C; Koutras A; Zagouri F; Gogas H; Fountzilas G
Breast; 2024 Feb; 73():103668. PubMed ID: 38176305
[TBL] [Abstract] [Full Text] [Related]
7. clinical characteristics and prognosis of primary small cell carcinoma of the breast: a propensity score-matched, population-based study.
Yin L; Yin AH; Pu CC
BMJ Open; 2023 Dec; 13(12):e073841. PubMed ID: 38097248
[TBL] [Abstract] [Full Text] [Related]
8. Vascular endothelial growth factor (VEGF) -A, -C and VE-cadherin as potential biomarkers in early breast cancer patients.
Milovanović J; Vujasinović T; Todorović-Raković N; Greenman J; Hranisavljević J; Radulovic M
Pathol Res Pract; 2023 Dec; 252():154923. PubMed ID: 37948997
[TBL] [Abstract] [Full Text] [Related]
9. clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
Baba T; Kusumoto M; Kato T; Kurihara Y; Sasaki S; Oikado K; Saito Y; Endo M; Fujiwara Y; Kenmotsu H; Sata M; Takano T; Kato K; Hirata K; Katagiri T; Saito H; Kuwano K
Int J Clin Oncol; 2023 Dec; 28(12):1585-1596. PubMed ID: 37787866
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract] [Full Text] [Related]
11. GK-1 effectively reduces angiogenesis and prevents T cell exhaustion in a breast cancer murine experimental model.
Hernández-Aceves JA; Cervantes-Torres J; Torres-García D; Zuñiga-Flores FJ; Patiño-Chávez OJ; Peña Agudelo JA; Aguayo-Flores JE; Garfias Y; Montero-León L; Romero-Romero L; Pérez-Torres A; Fragoso G; Sciutto E
Cancer Immunol Immunother; 2023 Nov; 72(11):3825-3838. PubMed ID: 37736849
[TBL] [Abstract] [Full Text] [Related]
12. Real-world evidence of neoadjuvant chemotherapy for breast cancer treatment in a Brazilian multicenter cohort: Correlation of pathological complete response with overall survival.
Antonini M; Mattar A; Bauk Richter FG; Pannain GD; Teixeira MD; Amorim AG; Ferraro O; Guedes Lopes RC; Gebrim LH; Real JM
Breast; 2023 Dec; 72():103577. PubMed ID: 37722319
[TBL] [Abstract] [Full Text] [Related]
13. Combination Organelle Mitochondrial Endoplasmic Reticulum Therapy (COMET) for Multidrug Resistant breast cancer.
Milane LS; Dolare S; Ren G; Amiji M
J Control Release; 2023 Nov; 363():435-451. PubMed ID: 37717658
[TBL] [Abstract] [Full Text] [Related]
14. clinical and prognostic role of sarcopenia based on masticatory muscle index on MR images in patients with extranodal natural killer/T cell lymphoma, nasal type.
Xu T; Li Y; Liu Y; Ning B; Wu H; Wei Y
Ann Hematol; 2023 Dec; 102(12):3521-3532. PubMed ID: 37702822
[TBL] [Abstract] [Full Text] [Related]
15. Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate cancer.
Neeb A; Figueiredo I; Gurel B; Nava Rodrigues D; Rekowski J; Riisnaes R; Ferreira A; Miranda S; Crespo M; Westaby D; de Los Dolores Fenor de La Maza M; Guo C; Carmichael J; Grochot R; Tunariu N; Cato ACB; Plymate SR; de Bono JS; Sharp A
Lab Invest; 2023 Nov; 103(11):100245. PubMed ID: 37652207
[TBL] [Abstract] [Full Text] [Related]
16. Feasibility and efficacy of ultrasound-guided high-intensity focused ultrasound of breast fibroadenoma.
Liang M; Zhang Z; Zhang C; Chen R; Xiao Y; Li Z; Li T; Liu Y; Ling L; Xie H; Chen L; Liu X; Wang S; Xia T
Int J Hyperthermia; 2023; 40(1):2240548. PubMed ID: 37544652
[TBL] [Abstract] [Full Text] [Related]
17. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer.
Liu Z; Ding M; Qiu P; Pan K; Guo Q
Front Immunol; 2023; 14():1200282. PubMed ID: 37520534
[TBL] [Abstract] [Full Text] [Related]
18. Distinct genomic landscapes in radiation-associated angiosarcoma compared with other radiation-associated sarcoma histologies.
Dermawan JK; Chi P; Tap WD; Rosenbaum E; D'Angelo S; Alektiar KM; Antonescu CR
J Pathol; 2023 Aug; 260(4):465-477. PubMed ID: 37350195
[TBL] [Abstract] [Full Text] [Related]
19. Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival.
Takano EA; Younes MM; Meehan K; Spalding L; Yan M; Allan P; Fox SB; Redfern A; Clouston D; Giles GG; Christie EL; Anderson RL; Zethoven M; Phillips KA; Gorringe K; Britt KL
BMC Cancer; 2023 May; 23(1):459. PubMed ID: 37208678
[TBL] [Abstract] [Full Text] [Related]
20. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N; Fasching PA; Wuerstlein R; Degenhardt T; Lüftner D; Kates RE; Schumacher J; Räth P; Hoffmann O; Lorenz R; Decker T; Reinisch M; Göhler T; Staib P; Gluz O; Schinköthe T; Schmidt M;
Ann Oncol; 2023 Aug; 34(8):660-669. PubMed ID: 37201751
[TBL] [Abstract] [Full Text] [Related]
[Next]
